These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21127185)

  • 1. Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis.
    Tapan U; Seldin DC; Finn KT; Fennessey S; Shelton A; Zeldis JB; Sanchorawala V
    Blood; 2010 Dec; 116(23):5071-2. PubMed ID: 21127185
    [No Abstract]   [Full Text] [Related]  

  • 2. Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis.
    Sanchorawala V; Finn KT; Fennessey S; Shelton A; Doros G; Zeldis JB; Seldin DC
    Blood; 2010 Sep; 116(11):1990-1. PubMed ID: 20847211
    [No Abstract]   [Full Text] [Related]  

  • 3. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide.
    Palladini G; Russo P; Foli A; Milani P; Lavatelli F; Obici L; Nuvolone M; Brugnatelli S; Invernizzi R; Merlini G
    Ann Hematol; 2012 Jan; 91(1):89-92. PubMed ID: 21533608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis.
    Kastritis E; Terpos E; Roussou M; Gavriatopoulou M; Pamboukas C; Boletis I; Marinaki S; Apostolou T; Nikitas N; Gkortzolidis G; Michalis E; Delimpasi S; Dimopoulos MA
    Blood; 2012 Jun; 119(23):5384-90. PubMed ID: 22517904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide in the treatment of plasma cell dyscrasia: state of the art and perspectives.
    Palumbo A; Cavallo F
    Haematologica; 2013 May; 98(5):660-1. PubMed ID: 23633539
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials].
    Adam Z; Sčudla V; Krejčí M; Cermáková Z; Pour L; Král Z
    Vnitr Lek; 2013 Jan; 59(1):37-58. PubMed ID: 23428001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolving role of lenalidomide in the treatment of hematologic malignancies.
    Kastritis E; Dimopoulos MA
    Expert Opin Pharmacother; 2007 Mar; 8(4):497-509. PubMed ID: 17309344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of plasma cell dyscrasias with lenalidomide.
    Dimopoulos MA; Kastritis E; Rajkumar SV
    Leukemia; 2008 Jul; 22(7):1343-53. PubMed ID: 18509355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis.
    Hussain AS; Hari P; Brazauskas R; Arce-Lara C; Pasquini M; Hamadani M; D'Souza A
    Am J Hematol; 2015 Nov; 90(11):E212-3. PubMed ID: 26284951
    [No Abstract]   [Full Text] [Related]  

  • 10. [Current treatment of AL amyloidosis].
    Desport E; Moumas E; Abraham J; Delbès S; Lacotte-Thierry L; Touchard G; Fermand JP; Bridoux F; Jaccard A
    Nephrol Ther; 2011 Nov; 7(6):467-73. PubMed ID: 21497573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
    Mahmood S; Venner CP; Sachchithanantham S; Lane T; Rannigan L; Foard D; Pinney JH; Gibbs SD; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
    Br J Haematol; 2014 Sep; 166(6):842-8. PubMed ID: 24930361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide in multiple myeloma.
    Thomas SK; Richards TA; Weber DM
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma.
    Sviggum HP; Davis MD; Rajkumar SV; Dispenzieri A
    Arch Dermatol; 2006 Oct; 142(10):1298-302. PubMed ID: 17043184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kidney dysfunction during lenalidomide treatment for AL amyloidosis.
    Specter R; Sanchorawala V; Seldin DC; Shelton A; Fennessey S; Finn KT; Zeldis JB; Dember LM
    Nephrol Dial Transplant; 2011 Mar; 26(3):881-6. PubMed ID: 20693160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.
    Kastritis E; Roussou M; Gavriatopoulou M; Migkou M; Kalapanida D; Pamboucas C; Kaldara E; Ntalianis A; Psimenou E; Toumanidis ST; Tasidou A; Terpos E; Dimopoulos MA
    Am J Hematol; 2015 Apr; 90(4):E60-5. PubMed ID: 25580702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.
    Sanchorawala V; Wright DG; Rosenzweig M; Finn KT; Fennessey S; Zeldis JB; Skinner M; Seldin DC
    Blood; 2007 Jan; 109(2):492-6. PubMed ID: 16960148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of B-Type Natriuretic Peptide for Detecting Cardiac Involvement in Immunoglobulin Amyloidosis.
    Kimishima Y; Yoshihisa A; Kiko T; Yokokawa T; Miyata-Tatsumi M; Misaka T; Oikawa M; Kobayashi A; Takeishi Y
    Int Heart J; 2019 Sep; 60(5):1106-1112. PubMed ID: 31484874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure.
    Palladini G; Foli A; Milani P; Russo P; Albertini R; Lavatelli F; Obici L; Perlini S; Moratti R; Merlini G
    Am J Hematol; 2012 May; 87(5):465-71. PubMed ID: 22389105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide for the treatment of B-cell malignancies.
    Chanan-Khan AA; Cheson BD
    J Clin Oncol; 2008 Mar; 26(9):1544-52. PubMed ID: 18285605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uninvolved immunoglobulins predicting hematological response in newly diagnosed AL amyloidosis.
    Muchtar E; Magen H; Itchaki G; Cohen A; Rosenfeld R; Shochat T; Kornowski R; Iakobishvili Z; Raanani P
    Leuk Res; 2016 Feb; 41():56-61. PubMed ID: 26658109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.